[1] A substantial body of randomized-controlled trial evidence has demonstrated that beta-blockers reduce mortality in patients with systolic HF. [2] [5] Despite this trial evidence, and subsequent consensus clinical practice guidelines [6], many of these patients are not receiving beta-blockers [7], [8] and proven therapy has only slowly disseminated into practice.
Despite this trial's significant results, some methodological constraints such as its small sample size (N = 10) and large number of outcome measures limited the generalisability of its findings.
Power to detect significant associations with treatment dose was quite limited despite that this trial of EDI enrolled one of the largest samples reported in L/LMIC.
Also notable was the comparatively low proportion of trials from lower middle income countries in the Oral Health and Breast Cancer groups; however, despite this, these trials contributed a larger proportion to the overall number of participants (84.3% (n=194 439/230 584) and 45.2% (n=672 626/1 489 628) of participants, respectively).
Despite this, clinical trials evaluating adjuvant chemotherapy in this age group are sparse.
Despite this, clinical trials of anti-endotoxin monoclonal antibodies [ 3, 4] and cytokine antagonists have proved unsuccessful in controlling either sepsis or SIRS [ 5].
Despite this, few trials have been conducted to assess the effectiveness of interventions to support population-wide implementation of such initiatives.
18 24 Despite this, these trials reported conflicting results in both the duration of mechanical ventilation and weaning, possibly because of differences in the populations of patients studied or usual practice within the intensive care units.
Surprisingly, despite this, early trials of riluzole in patients with amyotrophic lateral sclerosis demonstrated small but significant benefits (Bensimon et al., 1994; Lacomblez et al., 1996; Miller et al., 2007).
